Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
Por:
Burkhardt, N, Mrowietz, U, Carrascosa, JM, Fernandez-Penas, P, Guede, D, Wilhelm, S, Dossenbach, M and Julien, D
Publicada:
1 may 2017
Resumen:
Filiaciones:
Burkhardt, N:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Mrowietz, U:
Univ Med Ctr Schlewsig Holstein, Campus Kiel, Kiel, Germany
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
Fernandez-Penas, P:
Westmead Hosp, Westmead, NSW, Australia
Guede, D:
Clinbay, Genappe, Belgium
Wilhelm, S:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Dossenbach, M:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Julien, D:
CHU Lyon, Lyon, France
|